Sankala Group’s AbbVie ABBV Stock Holding History

Sankala Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$534K	Sell	2,071 -34	-2%	-$7.32K	0.36%	71
2026 Q1	$446K	Hold	2,105	–	–	0.36%	62
2025 Q4	$489K	Buy	+2,105	New	+$480K	0.39%	63

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sankala Group's ABBV Position: Q2 2026 in Review

Sankala Group reduced its AbbVie (ABBV) stake by 1.6% in Q2 2026, selling an estimated $7.32K and leaving 2,071 shares worth $534K. The position accounts for 0.36% of the portfolio, ranked #71.

Sankala Group first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,232 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Sankala Group held 2,071 shares of AbbVie worth $534K as of Q2 2026.
Sankala Group sold 34 AbbVie shares in Q2 2026, an estimated $7.32K.
AbbVie made up 0.36% of Sankala Group's portfolio in Q2 2026, its #71 holding.
Sankala Group first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,232 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sankala Group's 13F filing for Q2 2026, filed 18 Aug 2026.